Avantor (AVTR) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
7 May, 2026Opening remarks and agenda
Meeting called to order at 11:00 A.M. with board members and key executives present.
Meeting conducted virtually with procedural rules and materials accessible online.
Quorum confirmed with 94% of outstanding shares represented.
Shareholder proposals
Election of nine directors recommended by the board for the next term.
Advisory vote on executive compensation recommended for approval.
Advisory vote on frequency of say-on-pay votes, with board recommending annual votes.
Ratification of Deloitte & Touche LLP as independent auditor for 2026 recommended.
Overview of voting outcomes
All director nominees elected by majority vote.
Executive compensation and annual say-on-pay frequency approved.
Deloitte & Touche LLP ratified as auditor.
Final results to be filed in Form 8-K within four business days.
Latest events from Avantor
- Organic growth, stronger margins, and IPO-funded deleveraging marked 2019.AVTR
Q4 2019 - Biopharma-led growth lifted sales, margins and cash flow despite uneven pandemic impacts.AVTR
Q4 2020 - 11.3% organic growth, 190-bps margin expansion and $4B+ deployed across three acquisitions.AVTR
Q4 2021 - Core growth and margin gains offset FX headwinds as cash funded debt reduction and expansion.AVTR
Q4 2022 - Organic growth returned in both segments as guidance rose and net debt declined.AVTR
Q3 2026 - FY23 sales and EBITDA fell, while free cash flow topped $723M amid weak demand.AVTR
Q4 2023 - Q2 2026 delivered higher sales, strong cash flow, and raised guidance amid improved segment results.AVTR
Q2 2026 - Q2 2025 net sales and margins declined, with guidance cut and a CEO transition announced.AVTR
Q2 2025 - Q4 growth, margin gains, and strong cash flow support continued improvement and deleveraging in 2025.AVTR
Q4 2024